COVID19 vaccine is now offered only for High-Risk Eligible Populations . Kindly call pharmacy to schedule an appointment.
One additional dose of COVID-19 vaccine is recommended for previously vaccinated individuals who have completed their primary series and are at increased risk of SARS-CoV-2 infection including:
- Adults 65 years of age and older.
-
- NACI recommends that those 80 years and older should receive one additional dose of vaccine while those 65 to 79 years of age may receive an additional dose of vaccine.
- Adult residents of long-term care homes and other congregate living settings for seniors.
- Individuals 6 months of age and older who are moderately to severely immunocompromised (due to specific underlying conditions or treatments, detailed in the updated and attached fact sheet).
- Individuals 55 years and older who identify as First Nations, Inuit, or Metis and their non-Indigenous household members who are 55 years and older.
Individuals who are not included in the list of eligible high-risk populations are not recommended to receive dose(s) in the spring regardless of if dose(s) were received in the fall. These individuals are recommended to be vaccinated in the fall during the next annual COVID-19 vaccine program (i.e., 2025/2026) to ensure optimal protection against circulating strains.
As indicated by NACI, the following individuals are considered to be moderately to severely immunocompromised and are recommended to receive an additional dose(s) as detailed in the immunization schedules section below:
• Solid tumour or hematologic malignancies or treatments for these conditions.
• Solid-organ transplant and taking immunosuppressive therapy.
• Hematopoietic stem cell transplant (HSCT) (within 2 years of transplantation or taking immunosuppression therapy).
• Immunocompromised due to chimeric antigen receptor (CAR) T cell therapy targeting lymphocytes.
• Moderate to severe primary immunodeficiency with associated humoral and/or cell mediated immunodeficiency or immune dysregulation.
• HIV with AIDS-defining illness or TB diagnosis in last 12 months before starting vaccine series, or severe immune compromise with CD4 <200 cells/µL or CD4 <15%, or without HIV viral suppression.
• Recent treatment with the following categories of immunosuppressive therapies: anti-B cell therapies (monoclonal antibodies targeting CD19, CD20 and CD22), high-dose systemic corticosteroids, alkylating agents, antimetabolites, or tumor necrosis factor (TNF) inhibitors and other biologic agents that are significantly immunosuppressive.
• Chronic kidney disease on dialysis
COVID19 Test kits are only available for purchase.
